114 related articles for article (PubMed ID: 8043545)
1. Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125.
Davies AP; Oram D
Br J Obstet Gynaecol; 1994 Jul; 101(7):632-3. PubMed ID: 8043545
[No Abstract] [Full Text] [Related]
2. Effect of tibolone on postmenopausal women with myomas.
Gregoriou O; Vitoratos N; Papadias C; Konidaris S; Costomenos D; Chryssikopoulos A
Maturitas; 1997 Jun; 27(2):187-91. PubMed ID: 9255754
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis between uterine myoma and endometriosis using CA 125 as a new tumor marker of ovarian carcinoma.
Takahashi K; Kijima S; Yoshino K; Shibukawa T; Murao F; Kitao M
Asia Oceania J Obstet Gynaecol; 1986 Mar; 12(1):99-103. PubMed ID: 3459417
[No Abstract] [Full Text] [Related]
4. Endometrial adenocarcinoma after prolonged tibolone therapy.
Nassar AH; Khalil AM; Seoud MA; Usta IM
Int J Gynaecol Obstet; 2005 Jul; 90(1):78-9. PubMed ID: 15913616
[No Abstract] [Full Text] [Related]
5. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
[No Abstract] [Full Text] [Related]
6. Serum CA-125 levels in the diagnosis and management of endometriosis.
Lanzone A; Marana R; Muscatello R; Fulghesu AM; Dell'Acqua S; Caruso A; Mancuso S
J Reprod Med; 1991 Aug; 36(8):603-7. PubMed ID: 1834843
[TBL] [Abstract][Full Text] [Related]
7. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
[TBL] [Abstract][Full Text] [Related]
8. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
Biglia N; Maffei S; Lello S; Nappi RE
Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
[TBL] [Abstract][Full Text] [Related]
9. [Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma].
Takahashi K; Kijima S; Yoshino K; Shibukawa T; Moriyama M; Iwanari O; Sawada K; Matsunaga I; Murao F; Kitao M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr; 37(4):591-5. PubMed ID: 3857281
[TBL] [Abstract][Full Text] [Related]
10. Endometrial antibodies versus CA-125 for the detection of endometriosis.
Wild RA; Hirisave V; Bianco A; Podczaski ES; Demers LM
Fertil Steril; 1991 Jan; 55(1):90-4. PubMed ID: 1986975
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling.
Hanifi-Moghaddam P; Boers-Sijmons B; Klaassens AH; van Wijk FH; den Bakker MA; Ott MC; Shipley GL; Verheul HA; Kloosterboer HJ; Burger CW; Blok LJ
J Mol Med (Berl); 2007 May; 85(5):471-80. PubMed ID: 17226044
[TBL] [Abstract][Full Text] [Related]
12. Short and long term effects of tibolone in postmenopausal women.
Formoso G; Perrone E; Maltoni S; Balduzzi S; D'Amico R; Bassi C; Basevi V; Marata AM; Magrini N; Maestri E
Cochrane Database Syst Rev; 2012 Feb; (2):CD008536. PubMed ID: 22336846
[TBL] [Abstract][Full Text] [Related]
13. The LIBERATE tibolone trial in breast cancer survivors.
Speroff L
Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
[No Abstract] [Full Text] [Related]
14. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
Lyytinen H; Ylikorkala O
Duodecim; 2011; 127(3):235-42. PubMed ID: 21438346
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor (IGF)-I levels in postmenopausal women receiving tibolone.
Hopkins KD; Parker JR; Lehmann ED; Rymer J; Holly JM; Fogelman I; Cwyfan-Hughes S; Teale JD; Gosling RG
Horm Metab Res; 1995 Aug; 27(8):387-8. PubMed ID: 7590630
[No Abstract] [Full Text] [Related]
16. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.
Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B
Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497
[TBL] [Abstract][Full Text] [Related]
17. Prognostic potential of serum CA 125 levels in danazol-treated patients with external endometriosis: a preliminary study.
Takahashi K; Yoshino K; Kusakari M; Katoh S; Shibukawa T; Kitao M
Int J Fertil; 1990; 35(4):226-9. PubMed ID: 1977715
[TBL] [Abstract][Full Text] [Related]
18. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
19. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
